Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Article Immunology

Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales

Marco Falcone et al.

Summary: This study aimed to compare the outcomes of patients with MBL-producing Enterobacterales bloodstream infections treated with CAZ-AVI + ATM or other active antibiotics. The results showed that CAZ-AVI + ATM was associated with lower 30-day mortality, lower clinical failure at day 14, and shorter length of stay.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Immunology

Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review

Kelly A. Cairns et al.

Summary: Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) pose a emerging threat in transplant recipients, often resulting in high mortality due to limited treatment options and toxicities. A novel approach using a combination of ceftazidime/avibactam with aztreonam has shown promise in successfully treating invasive MBL-CPE infections, offering a new treatment option with reduced drug interactions and toxicity for high-risk patients.

TRANSPLANT INFECTIOUS DISEASE (2021)

添加到收藏夹

Review Infectious Diseases

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales

Xing Tan et al.

Summary: This review outlines recent advancements in diagnostic and treatment strategies for infections caused by MBL-producing Enterobacterales, emphasizing the importance of detecting beta-lactamase in the clinic and current molecular platforms available for identifying MBLs. The review also discusses the potential use of antibiotics like ceftazidime-avibactam and cefiderocol for treating infections caused by MBL-producing Enterobacterales, as well as promising MBL inhibitors in development to improve treatment outcomes.

INFECTION AND DRUG RESISTANCE (2021)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This guidance document provides recommendations for the treatment of antimicrobial-resistant infections caused by ESBL-E, CRE, and DTR-P. aeruginosa, with a focus on the United States. It discusses empiric treatment selection, duration of therapy, and other management considerations for both adults and children. The current version of the guidance is valid as of September 17, 2020, and will be updated periodically.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology